An octapeptide, TBI-22 (Lys-Gly-Val-TyrIle-His-Ala-Leu), inhibited binding of angiotensin II by a solubilized angiotensin receptor partially purified from rabbit liver. This inhibition appears to result from competition for binding to the same receptor. Radioiodinated TBI-22, like angiotensin I, bound to the solubilized receptor with an affinity such that the binding was inhibited 50% by unlabeled or angiotensin HI at nanomolar concentrations. The binding reaction, like that for angiotensin HI, required pchloromercuriphenylsulfonic acid and was reversed in the presence of dithiothreitol. TBI-22 and angiotensin II share the sequence Val-Tyr-Ile-His; this tetrapeptide alone, however, did not inhibit binding of angiotensin II. Replacement of the tyrosine residue by aspartic acid in TBI-22 greatly reduced the ability of the peptide to compete with angiotensin H for binding, suggesting an important contribution of this residue to the configuration required for revognition by the receptor.
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The renin-angiotensin system is involved in the regulation of blood pressure (1) . Angiotensin II is the biologically active component of this physiological system (2) . Angiotensin II is a potent vasopressor agent as a consequence of its contractive effect on blood vessels (2) , its stimulation of aldosterone secretion by the adrenal cortex (3) , and its action on the central nervous system (4) . These and other effects of angiotensin II are mediated by a specific receptor(s) on the surface of its target cells (reviewed in ref. 5) .
Angiotensin-converting enzyme (reviewed in ref. 6 ) is a dipeptidyl carboxypeptidase that cleaves angiotensin I to angiotensin II. The use of drugs that inhibit angiotensinconverting enzyme (7, 8) has been shown to be an effective antihypertensive therapy. Angiotensin-converting enzyme possesses broad substrate specificity, and therefore its inhibition is likely to influence the metabolism of peptides unrelated to the renin-angiotensin system. An antagonist targeted at the angiotensin receptor might represent a more physiologically specific agent for antihypertensive therapy.
Analogs of angiotensin II with substitutions of the carboxylterminal residue have shown promise in this regard (9) (10) (11) . However, jt may be that identification of determinants actually recognized by the receptor will be necessary to expedite development of the desired antagonist. To obtain this type of information, examination of the binding of putative ligands by isolated receptor may be useful. To date, there have been few such studies, and virtually all of them have been carried out with intact membrane fractions (5) . Here, we report the binding of an octapeptide and some of its analogs and derivatives to a solubilized angiotensin II receptor partially purified from rabbit liver.
MATERIALS AND METHODS
III-labeled angiotensin II ('l25-angiotensin II; 1400 puCi/nmol; 1 Ci = 37 GBq) was purchased from New England Nuclear. t-Butoxycarbonyl (Boc) derivatives of amino acids were from Peninsula Laboratories (Belmont, CA). Diisopropylcarbodiimide and 1-hydroxybenzotriazole were products of Aldrich.
Peptides were synthesized by the solid-phase procedure (12) , using an automated synthesizer, model 9500 from Biosearch (San Rafael, CA). The first amino acid was esterified to chloromethylated polystyrene-divinylbenzene copolymer (Bio-Rad; 1% cross-linked, 1.34 meq/g) as described (13) . Subsequent amino acids were coupled twice by using diisopropylcarbodiimide. In general, the Boc group was removed by treatment of the resin containing protected peptide for 20 min with 45% trifl uoroacetic acid in dichloromethane (vol/vol) followed by two neutralizations of 5 (15) .
TBI-22 was radiolabeled by a modification of the method of Greenwood et al. (16) . The peptide (10 nmol) was incubated at 20'C for 30 sec with 4 mCi of Na125I (Amersham) in 70 Al of0.5 M potassium phosphate buffer, pH 7.4, containing 10 ,ug of chloramine T. The reaction was stopped by addition of 1 mg of 2-mercaptoethanolamine (Sigma) followed by 0. fTo whom reprint requests should be addressed.
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nated TBI-22 (125I-TBI-22; 120 ,uCi/nmol) was eluted with glacial acetic acid and lyophilized.
The angiotensin II receptor was isolated as described (17) II to the partially purified receptor in a dose-dependent manner (Fig. lA) (17) . The data on binding of radioiodinated TBI-22 thus provide strong evidence that this peptide is bound by the angiotensin II receptor and that it inhibits the binding of angiotensin II by competing for the same binding site.
As anticipated from these results, unlabeled TBI-22 inhibited the binding of 3 nM radioiodinated TBI-22 at somewhat lower concentrations than did angiotensin II (Fig. 1B) Lys-Gly-Val-Tyr-Met-His-Ser-Leu 6 *Determined from an inhibition dose-response curve composed of at least four concentrations; >>10,000 denotes complete lack of inhibition at 10 MM.
required concentrations of both unlabeled peptides were proportionately higher, because of the higher concentration of labeled TBI-22 used. Use of the higher concentration of labeled material was required due to a lower specific radioactivity of the labeled TBI-22.
Competition for Binding to the Angiotensin Receptor by Peptides Related to TBI-22. Table 2 presents IC50 values of various unlabeled peptides; respective abilities to compete with 0.25 nM radioiodinated angiotensin II for binding to its receptor were measured. TBI-33, the all-D analog of TBI-22, and TBI-48, which contains its residues in reversed sequence, did not inhibit binding, indicating biological specificity for the binding of TBI-22. Several derivatives containing groups that might be expected to enhance metabolic stability were examined. TBI-27, the nonapeptide resulting from prolyl addition at the carboxyl terminus of TBI-22, exhibited the same IC50 value as TBI-22. However, the acetylated derivative of the nonapeptide, TBI-30, was approximately 1/40th as inhibitory. Similarly, whereas amidation of TBI-22 yielded a peptide (TBI-29) with an IC50 value only 5-fold higher than the parent compound, further derivatization by acetylation was associated with an additional 60-fold increase in the IC50 value for the resulting doubly blocked peptide (TBI-26).
Other peptide fragments and analogs of TBI-22 were analyzed to identify parts of its structure that might be required for recognition by the receptor. Although TBI-22 and angiotensin II possess the same residues in positions 3 through 6, a tetrapeptide composed of this sequence (TBI-75), failed to inhibit. The carboxyl-terminal tetrapeptide of TBI-22 (TBI-76) was similarly inactive, and even the carboxyl-terminal hexapeptide (TBI-77) was relatively inactive, with an IC50 value of 2500 nM. These data resemble qualitatively those reported for inhibition of angiotensin II binding to canine adrenal membranes by carboxyl-terminal fragments of angiotensin 11 (3) . TBI-31, approximately 1/600th as inhibitory as TBI-22, contains Asp-Met instead of Tyr-Ile at positions 4 and 5. TBI-61, which also contains a methionine residue in position 5, was as potent as TBI-22 at inhibiting angiotensin II binding. Thus, the decrease in inhibitory activity of TBI-31 relative to TBI-22 is apparently the consequence of substitution of an aspartic residue for tyrosine in position 4; this suggests that tyrosine is important in binding of ligand to the receptor.
Immunological Studies on TBI-22 and Angiotensin II. Antibodies developed against either TBI-22 or angiotensin II were incapable of binding both peptides with comparable avidity. As shown in Table 3 , antibodies against TBI-22 failed to bind angiotensin II, and those against angiotensin II bound more tightly to angiotensin II than TBI-22, although some binding of the latter was detectable. The antigenic determinants of these peptides thus seem to differ from those recognized by the receptor.
DISCUSSION
There is limited information describing the effect of substitutions within the angiotensin II molecule on its binding by cell-free receptor preparations. Studies with intact membranes from adrenal cortex have suggested that the requisite peptide conformation depends on the carboxyl-terminal tetrapeptide of the molecule (5). TBI-22 shares only two of these four residues with angiotensin II, and TBI-61 shares only one. TBI-27, the nonapeptide analog of TBI-22 with a carboxyl-terminal proline residue, is bound as well as the parent compound. Although TBI-22 shares residues 3 through 6 with angiotensin II, these residues as a tetrapeptide do not contain the structural signal required for recognitioni.e. it is inactive in the binding reaction.
It seems clear, however, that one of these residues, tyrosine in position 4, is important for the appropriate conformation, since replacement by aspartic acid yields an octapeptide that is less tightly bound. Replacement of the tyrosine residue in position four of angiotensin II with phenylalanine as in [Phe4]-and [Phe4,Tyr8]angiotensin II results in decreased binding by particulate preparations (22, 23) . Our binding data with the solubilized partially purified hepatic receptor and fragments of TBI-22 are also consistent with those described for angiotensin II fragments binding to adrenal membranes (3, 5) , suggesting that most of the length of the octapeptide is required for assumption of the recognized configuration. An angiotensin antagonist acting at the receptor level may represent the most physiologically specific agent for pharmacological blockage of angiotensin II. Inhibition of renin and converting enzyme, while diminishing production of angiotensin II, might alter the metabolism of other proteins and peptides. A receptor antagonist would also offer the advantages of preventing the effects of angiotensin II potentially generated by other enzymes such as tonin (24) , and of angiotensin I, which, although only weakly bound by the receptor (5, 17) , is markedly elevated in the circulation when converting enzyme is inhibited (25) . The promise of an angiotensin receptor antagonist stimulated much research in the 1960s and early 1970s (9) (10) (11) . Recent technological progress, including relative ease of peptide synthesis, availability of partially purified receptor preparations for binding studies, and advances in computer modeling, suggest that development of a drug that acts at the receptor level has become a feasible goal. These studies on the binding of TBI-22 and related analogs by the solubilized receptor, and investigations on the binding of angiotensin II and its fragments by particulate fractions (5) , suggest that the receptor recognizes a specific configuration. This conformation is probably generated from at least seven amino acid residues. The tyrosine in position four of both angiotensin II and TBI-22 is critical. Identification of the preferred conformation and its simulation by a compound resistant to peptidase action might represent an important step in development of the desired antagonist. A compound that exhibits the desired biochemical property of binding to the isolated receptor must also be examined in more integrated systems (such as smooth muscle preparations and intact animals) to determine its pharmacological properties, including its antagonistic and agonistic actions.
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